1. Home
  2. PNR vs ILMN Comparison

PNR vs ILMN Comparison

Compare PNR & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pentair plc.

PNR

Pentair plc.

HOLD

Current Price

$88.28

Market Cap

16.7B

Sector

Industrials

ML Signal

HOLD

Logo Illumina Inc.

ILMN

Illumina Inc.

HOLD

Current Price

$122.55

Market Cap

20.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PNR
ILMN
Founded
1966
1998
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Medical Specialities
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
16.7B
20.4B
IPO Year
2003
2000

Fundamental Metrics

Financial Performance
Metric
PNR
ILMN
Price
$88.28
$122.55
Analyst Decision
Buy
Hold
Analyst Count
14
17
Target Price
$116.62
$124.24
AVG Volume (30 Days)
1.3M
1.7M
Earning Date
04-21-2026
05-07-2026
Dividend Yield
1.22%
N/A
EPS Growth
5.88
170.87
EPS
3.96
5.45
Revenue
N/A
$4,343,000,000.00
Revenue This Year
$4.21
$6.52
Revenue Next Year
$4.60
$5.49
P/E Ratio
$22.29
$22.49
Revenue Growth
N/A
N/A
52 Week Low
$74.25
$68.70
52 Week High
$113.95
$155.53

Technical Indicators

Market Signals
Indicator
PNR
ILMN
Relative Strength Index (RSI) 28.63 46.25
Support Level N/A $114.88
Resistance Level $108.26 $135.68
Average True Range (ATR) 2.48 4.25
MACD -0.60 0.03
Stochastic Oscillator 2.30 37.31

Price Performance

Historical Comparison
PNR
ILMN

About PNR Pentair plc.

Pentair is a global leader in the water treatment industry, with 10,000 employees and a presence in 25 countries. Its business is organized into three segments: pool, water technologies, and flow. The company offers a wide range of water solutions, including energy-efficient swimming pool equipment, filtration solutions, and commercial and industrial pumps. Pentair generated approximately $4.2 billion in revenue in 2025.

About ILMN Illumina Inc.

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Share on Social Networks: